Form 4 for TWST Twist Bioscience Corp
Accepted 2025-10-30 00:00:00 ET · period of report 2025-10-28 · accession 0001214659-25-015584 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-10-30 | 2025-10-28 | TWST | Leproust Emily M. | CEO, Dir | A - Grant | $0.00 | +169.0K | 770.2K | +28% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-28 | A | A | 168,976 | $0.00 | 770,188 | D | — | — | (F1) Represents Performance Stock Units for which target criteria was determined to have been met on October 28, 2025. 60% of the PSUs remain subject to time-based vesting and will vest on October 1, 2026, subject to continued service or acceleration of vesting as provided in the award agreement. |